PTK2 and cancer: We believe that the inhibitory effects of α-cubebenoate on CT26 cancer growth are associated with the inhibition of adhesion ability via regulation of the FAK/MLC signaling pathway and with the suppression of migration ability via regulation of the PI3K/AKT signaling pathway.